{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,18]],"date-time":"2026-01-18T21:05:58Z","timestamp":1768770358281,"version":"3.49.0"},"reference-count":9,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2013,3,1]],"date-time":"2013-03-01T00:00:00Z","timestamp":1362096000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2015,12,2]],"date-time":"2015-12-02T00:00:00Z","timestamp":1449014400000},"content-version":"vor","delay-in-days":1006,"URL":"https:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Journal of Thoracic Oncology"],"published-print":{"date-parts":[[2013,3]]},"DOI":"10.1097\/jto.0b013e318282709c","type":"journal-article","created":{"date-parts":[[2013,2,12]],"date-time":"2013-02-12T12:05:06Z","timestamp":1360670706000},"page":"369-372","source":"Crossref","is-referenced-by-count":32,"title":["Phase II Study of Docetaxel in Combination with Everolimus for Second- or Third-Line Therapy of Advanced Non\u2013Small-Cell Lung Cancer"],"prefix":"10.1016","volume":"8","author":[{"given":"Suresh S.","family":"Ramalingam","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Taofeek K.","family":"Owonikoko","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Madhusmita","family":"Behera","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Janakiraman","family":"Subramanian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nabil F.","family":"Saba","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Scott A.","family":"Kono","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anthony A.","family":"Gal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gabriel","family":"Sica","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R. Donald","family":"Harvey","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhengjia","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carmen M.","family":"Klass","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dong M.","family":"Shin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haian","family":"Fu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shi-yong R.","family":"Sun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ramaswamy","family":"Govindan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fadlo R.","family":"Khuri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1097\/JTO.0b013e318282709c_bib1","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/S1556-0864(15)31524-0","article-title":"Targeting mTOR signaling for lung cancer therapy","volume":"1","author":"Sun","year":"2006","journal-title":"J Thorac Oncol"},{"key":"10.1097\/JTO.0b013e318282709c_bib2","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1158\/1535-7163.1605.3.12","article-title":"Akt up-regulation increases resistance to microtubule-directed chemotherapeutic agents through mammalian target of rapamycin","volume":"3","author":"VanderWeele","year":"2004","journal-title":"Mol Cancer Ther"},{"key":"10.1097\/JTO.0b013e318282709c_bib3","doi-asserted-by":"crossref","first-page":"1674","DOI":"10.1093\/annonc\/mdp060","article-title":"Efficacy of everolimus (RAD001) in patients with advanced NSCLC previously treated with chemotherapy alone or with chemotherapy and EGFR inhibitors","volume":"20","author":"Soria","year":"2009","journal-title":"Ann Oncol"},{"key":"10.1097\/JTO.0b013e318282709c_bib4","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.1016\/j.ejca.2012.02.053","article-title":"Effects of the combination of RAD001 and docetaxel on breast cancer stem cells","volume":"48","author":"Zhang","year":"2012","journal-title":"Eur J Cancer"},{"key":"10.1097\/JTO.0b013e318282709c_bib5","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1002\/pros.20752","article-title":"RAD001 (Everolimus) inhibits growth of prostate cancer in the bone and the inhibitory effects are increased by combination with docetaxel and zoledronic acid","volume":"68","author":"Morgan","year":"2008","journal-title":"Prostate"},{"key":"10.1097\/JTO.0b013e318282709c_bib6","doi-asserted-by":"crossref","first-page":"3903","DOI":"10.1002\/cncr.25264","article-title":"Phase 1 and pharmacokinetic study of everolimus, a mammalian target of rapamycin inhibitor, in combination with docetaxel for recurrent\/refractory nonsmall cell lung cancer","volume":"116","author":"Ramalingam","year":"2010","journal-title":"Cancer"},{"key":"10.1097\/JTO.0b013e318282709c_bib7","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1093\/jnci\/92.3.205","article-title":"New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada","volume":"92","author":"Therasse","year":"2000","journal-title":"J Natl Cancer Inst"},{"key":"10.1097\/JTO.0b013e318282709c_bib8","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1056\/NEJMoa1109653","article-title":"Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer","volume":"366","author":"Baselga","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1097\/JTO.0b013e318282709c_bib9","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/S0140-6736(08)61039-9","article-title":"Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial","volume":"372","author":"Motzer","year":"2008","journal-title":"Lancet"}],"container-title":["Journal of Thoracic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1556086415327726?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1556086415327726?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,5,5]],"date-time":"2024-05-05T21:13:02Z","timestamp":1714943582000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1556086415327726"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,3]]},"references-count":9,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2013,3]]}},"alternative-id":["S1556086415327726"],"URL":"https:\/\/doi.org\/10.1097\/jto.0b013e318282709c","relation":{},"ISSN":["1556-0864"],"issn-type":[{"value":"1556-0864","type":"print"}],"subject":[],"published":{"date-parts":[[2013,3]]}}}